Skip to main content
  • English
  • Català
  • Español
Home
  • Company
    • Overview & History
    • Team
    • Join Oryzon
  • Epigenetics
    • Histone Code Hypothesis
    • Modulator Enzymes
    • LSD1 & Disease
    • Technology Platforms
    • Scientific Publications by Oryzon
  • Therapeutic Programs
    • Strategy
    • LSD1 & Cancer
    • Oryzon's Pipeline
  • Collaborative Research
    • Collaborative Projects
  • For Patient
    • Patient Information
  • Shareholders and Investors
    • Investor Information and News
    • Share Information
    • Events & Presentations
    • Financial Information & Downloads
    • Analyst Coverage
    • Corporate Governance
    • Corporate Social Responsibility
  • News & Press Releases
  • Contact
    • General Contact
    • Investor Contact
    • Email Alerts

News

Archive

  • 2019
  • 2018
  • 2017
  • 2016
  • 2015
  • 2014
  • 2013
  • 2012
  • 2011
  • 2010

News & Press Releases

31 May 2017
Oryzon Genomics to Participate in a Panel at the JMP Securities Life Sciences Conference and Present at the Jefferies 2017 Global Health Conference
16 May 2017
Oryzon announces appointment of new Chief Medical Officer and expansion of its Medical Department
9 May 2017
ORYZON Reports Financial Results and Corporate Update for the 1st Quarter, 2017
5 May 2017
Dr. Carlos Buesa, CEO and Founder of Oryzon, received the award for the Best Entrepreneur
24 April 2017
ORYZON Announces New Grant from Alzheimer’s Drug Discovery Foundation (ADDF) to develop a companion marker for its ORY-2001 epigenetic drug
3 April 2017
ORYZON presents data on the Phase I trial with ORY-2001 at the 13th International Conference on Alzheimer’s and Parkinson’s diseases
31 March 2017
Oryzon Raises €18 Million through a Private Placement with US and European Investors
20 March 2017
Oryzon to Present at the Sachs Associates 2nd Annual Neuroscience BioPartnering & Investment Forum
15 March 2017
ORYZON to Present at the 11th Annual BIO-Europe Spring International Partnering Conference
27 February 2017
ORYZON presented new preclinical data of ORY-2001 therapeutic activity in Multiple Sclerosis at ACTRIMS-2017

Pages

  • « first
  • ‹ previous
  • …
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • …
  • next ›
  • last »

epigen-logo

Epigenetic drugs for a better world.

United States

Oryzon Corporate
245 First Street, Suite 1800
Cambridge, MA 02142

T: (617) 444-8786
F: (617) 444- 8405
info@oryzon.com

Spain

Oryzon Genomics
Sant Ferran 74
08940 Cornellà de Llobregat, Barcelona, Spain

T: (+34) 93 515 1313
F: (+34) 93 377 4028
info@oryzon.com

Legal Advice
Privacy Policy

Investor Information

ISIN: ES0167733015 - ORY

Please contact us for investor information.

Contact Us

© 2019

Oryzon Genomics

All Rights Reserved

  • Legal Advice
  • Privacy Policy
  • Registered address: Carrera de San Jerónimo 15, 2ª planta, 28014 Madrid (Spain)